# BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma

> **NCT00061880** · PHASE1,PHASE2 · COMPLETED · sponsor: **BioCryst Pharmaceuticals**

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** forodesine hydrochloride

## Key facts

- **NCT ID:** NCT00061880
- **Lead sponsor:** BioCryst Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2005-01
- **Final completion:** 2008-01
- **Target enrollment:** — (—)
- **Last updated:** 2013-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00061880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00061880, "BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00061880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*